Knight TherapeuticsFRA:04K 73 Quick Ratio is 1.59 as of Mar. 2026, which is 36% below its 10-year median of 2.47. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.30. The stock has 6 warning signs investors should review. Among 994 Drug Manufacturers companies, Knight Therapeutics ranks better than 54.43% on this metric.
Knight Therapeutics has a quick ratio of 1.59. It generally indicates good short-term financial strength.
The historical rank and industry rank for Knight Therapeutics's Quick Ratio or its related term are showing as below:
FRA:04K'
s Quick Ratio Range Over the Past 10 Years
Min: 1.5 Med: 2.47 Max: 112.67
Current: 1.59
During the past 13 years, Knight Therapeutics's highest Quick Ratio was 112.67. The lowest was 1.50. And the median was 2.47.
FRA:04K's Quick Ratio is ranked better than 54.43% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs FRA:04K: 1.59
Knight Therapeutics (FRA:04K) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Knight Therapeutics Quick Ratio Related Terms
Knight Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Knight Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (FRA:04K) has a Quick Ratio of 1.59 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Knight Therapeutics and its competitors. This is 36% below median its historical median of 2.47. Over the past decade, Knight Therapeutics' Quick Ratio has ranged from 1.50 to 112.67. According to the industry distribution chart, Knight Therapeutics ranks #453 out of 994 companies in the Drug Manufacturers industry, placing it in the top 45.6%.
Is Knight Therapeutics' Quick Ratio too high?
Knight Therapeutics' current Quick Ratio of 1.59 is 36% below median its 10-year median of 2.47. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 112.67. The Drug Manufacturers industry median Quick Ratio is 1.45. Knight Therapeutics' value of 1.59 is 9.7% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #453 out of 994 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #453 out of 994 companies for Quick Ratio. This puts Knight Therapeutics in the upper half of its industry. The industry median Quick Ratio is 1.45. Knight Therapeutics' value of 1.59 is 9.7% above this benchmark. Historically, Knight Therapeutics' own Quick Ratio has ranged from 1.50 to 112.67 over the past decade. While the company's 10-year median is 2.47 vs. the industry median of 1.45, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current Quick Ratio of 1.59 is 9.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current Quick Ratio is 1.59, which is 36% below median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Quick Ratio of 1.59. The stock's GF Value™ is €5.30, compared to a current price of €5.80 — trading 9.4% above its estimated fair value. The current Quick Ratio is 1.59, which is 36% below median its 10-year median of 2.47 and 9.7% above the Drug Manufacturers industry median of 1.45. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Quick Ratio is 1.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (FRA:04K) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of €5.80 is trading 9.4% above its estimated GF Value™ of €5.30.
Key valuation signals for FRA:04K:
Quick Ratio: 1.59 (36% below median its 10-year median of 2.47)
GF Value™: €5.30 vs. price of €5.80 (9.4% above fair value)
Industry Position: 9.7% above the Drug Manufacturers median (#453 of 994)
No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for FRA:04K
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:04K has been successfully added to your 
